Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 5, 2014, Pages 696-704

  Choi, Inpyo ^a   Yoon, Suk Ran ^a   Park, Soo Yeon ^a   Kim, Hanna ^a   Jung, Sol Ji ^a   Jang, Ye Jin ^a   Kang, Minho ^a   Yeom, Young Il ^a   Lee, Jae Lyun ^b   Kim, Dae Young ^b   Lee, Young Shin ^b   Kang, Young Ah ^b   Jeon, Mijin ^b   Seol, Miee ^b   Lee, Jung Hee ^b   Lee, Je Hwan ^b   Kim, Hwa Jung ^b   Yun, Sung Cheol ^b   Lee, Kyoo Hyung ^b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Donor natural killer cell infusion; Human leukocyte antigen haploidentical hematopoietic cell transplantation

Indexed keywords

BUSULFAN; CD3 ANTIGEN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 21; INTERLEUKIN DERIVATIVE; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY; MYELOABLATIVE AGENT; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CANCER SURVIVAL; CELL CULTURE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DONOR; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; ENGRAFTMENT; FEMALE; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; INFUSION; LARGE CELL LYMPHOMA; LEUKAPHERESIS; LEUKEMIA REMISSION; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; TREATMENT DURATION; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL; TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; BUSULFAN; CHILD; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84897961037     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.01.031     Document Type: Article

References (42)

1. Ogawa H., Ikegame K., Yoshihara S., et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006, 12:1073-1084.
2. Rizzieri D.A., Koh L.P., Long G.D., et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. JClin Oncol 2007, 25:690-697.
3. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
4. Lee K.H., Lee J.H., Kim D.Y., et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 2011, 118:2609-2617.
5. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
6. Bashey A., Zhang X., Sizemore C.A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. JClin Oncol 2013, 31:1310-1316.
7. Herberman R.B., Nunn M.E., Holden H.T., Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975, 16:230-239.
8. Kiessling R., Klein E., Pross H., Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975, 5:117-121.
9. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
10. Vivier E., Raulet D.H., Moretta A., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
11. Verheyden S., Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008, 22:249-257.
12. Lundqvist A., Philip McCoy J., Samsel L., Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007, 109:3603-3606.
13. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
14. Parham P., McQueen K.L. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003, 3:108-122.
15. Ljunggren H.G., Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007, 7:329-339.
16. Passweg J.R., Tichelli A., Meyer-Monard S., et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004, 18:1835-1838.
17. Schulze A., Schirutschke H., Oelschlagel U., et al. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol 2008, 36:378-389.
18. Rizzieri D.A., Storms R., Chen D.F., et al. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:1107-1114.
19. Yoon S.R., Lee Y.S., Yang S.H., et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplantation 2010, 45:1038-1046.
20. Shi J., Tricot G., Szmania S., et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br JHaematol 2008, 143:641-653.
21. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and invivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
22. Rubnitz J.E., Inaba H., Ribeiro R.C., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. JClin Oncol 2010, 28:955-959.
23. Iliopoulou E.G., Kountourakis P., Karamouzis M.V., et al. Aphase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010, 59:1781-1789.
24. Curti A., Ruggeri L., D'Addio A., et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011, 118:3273-3279.
25. Mrozek E., Anderson P., Caligiuri M.A. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996, 87:2632-2640.
26. Lee K.H., Lee J.H., Kim D.Y., et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without exvivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transplant 2009, 15:61-72.
27. Kanoh S., Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010, 23:590-615.
28. Cutler C., Antin J.H. Manifestations and treatment of acute graft-versus-host disease. Thomas' hematopoietic cell transplantation 2008, 1287-1303. Wiley-Blackwell, Chichester, West Sussex, UK. 4th ed. F.R. Appelbaum, S.J. Forman, R.S. Negrin, K.G. Blume (Eds.).
29. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
30. Klein J.P., Moeschberger M.L. Survival analysis. Techniques of censored and truncated data 2003, Springer-Verlag, New York, NY. 2nd ed.
31. Gray R.J. Aclass of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
32. Fine J.P., Gray R.J. Aproportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc 1999, 94:495-509.
33. Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-732.
34. Leung W. Use of NK cell activity in cure by transplant. Brit J Haematol 2011, 155:14-29.
35. Krebs P., Barnes M.J., Lampe K., et al. NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood 2009, 113:6593-6602.
36. Robbins S.H., Bessou G., Cornillon A., et al. Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathogens 2007, 3:e123.
37. Pende D., Spaggiari G.M., Marcenaro S., et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005, 105:2066-2073.
38. Park M.H., Hwang Y.S., Park K.S., et al. HLA haplotypes in Koreans based on 107 families. Tissue Antigen 1998, 51:347-355.
39. Kim H.J., Choi Y., Min W.S., et al. The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia. Transplantation 2007, 84:1082-1091.
40. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
41. Remberger M., Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005, 90:931-938.
42. Wang H., Grzywacz B., Sukovich D., et al. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood 2007, 110:1530-1539.